Publications by authors named "Maria E Silk"

Claim this Profile
B
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
Eric F Morand, Edward M Vital, Michelle Petri, Ronald van Vollenhoven, Daniel J Wallace, Maria E Silk

Lancet· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Michelle Petri, Ian N Bruce, Thomas Dörner, Yoshiya Tanaka, Eric F Morand, Maria E Silk

Lancet· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
Thomas Dörner, Ronald F van Vollenhoven, Andrea Doria, Bochao Jia, Jorge A Ross Terres, Maria E Silk

Arthritis Res Ther· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient Experiences, Satisfaction, and Expectations with Current Systemic Lupus Erythematosus Treatment: Results of the SLE-UPDATE Survey.
Julie A Birt, Monica A Hadi, Nashmel Sargalo, Ella Brookes, Paul Swinburn, Maria E Silk

Rheumatol Ther· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
Thomas Dörner, Yoshiya Tanaka, Michelle A Petri, Josef S Smolen, Daniel J Wallace, Maria E Silk

Lupus Sci Med· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
J
JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial.
Katherine R Tuttle, Frank C Brosius, Sharon G Adler, Matthias Kretzler, Ravindra L Mehta, Maria E Silk

Nephrol Dial Transplant· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
Daniel J Wallace, Richard A Furie, Yoshiya Tanaka, Kenneth C Kalunian, Marta Mosca, Maria E Silk

Lancet· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis